GeneDx Holdings Corp. (WGS) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

46/ 100

GoAI Score

Hold

Valuation

76

Undervalued

Sentiment

43

Mixed

Risk

71

High Risk

Momentum

38

Weakening

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Industry: Medical - Diagnostics & Research
Sector: Healthcare
Headquarters: US
CEO: Katherine A. Stueland
Listed since: Nov 4, 2020
Employees: 1,300

Market position

Day range

Current $85.99

$84.1601$87.99

52-week range

Current $85.99

$32.21$170.87

Open: $87.74
Previous close: $87.39
Volume: 304.44K; 0.26× average
Average volume: 1.15M; Average daily volume
Market cap: 2.56B USD
Beta: 2.01; Market reference 1
50-day average: $73.0533; +17.71% above average
200-day average: $84.8142; +1.39% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -23.62×
P/B (TTM): 10.46×
P/S (TTM): 5.64×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 68.20%
Operating margin: -13.34%
Net margin: -23.40%

Financial health

Debt / equity: 0.69×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

427.54M USD+39.97%

Operating income

−11.8M USD+49.16%

Net income

−21.02M USD+59.80%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	427.54M USD	305.45M USD	202.57M USD	234.69M USD	212.2M USD
Cost of goods sold	129.37M USD	111.05M USD	112.56M USD	261.44M USD	228.8M USD
Gross profit	298.17M USD	194.4M USD	90.01M USD	−26.75M USD	−16.6M USD
Research and development	72.03M USD	45.72M USD	58.27M USD	86.2M USD	105.16M USD
Selling, general, and administrative	239.22M USD	168.48M USD	194.71M USD	338.24M USD	318.73M USD
Operating expenses	311.25M USD	217.61M USD	270.6M USD	640.9M USD	429.55M USD
Interest income	—	—	1.11M USD	2.54M USD	79K USD
Interest expense	2.54M USD	3.03M USD	—	3.21M USD	2.84M USD
Depreciation and amortization	25.22M USD	21.95M USD	33.73M USD	59.31M USD	21.81M USD
Operating income	−11.8M USD	−23.21M USD	−180.6M USD	−667.65M USD	−446.15M USD
Net income	−21.02M USD	−52.29M USD	−175.77M USD	−548.98M USD	−245.39M USD

Company facts updated Sep 7, 2026.

Earnings

EPS beat rate: 91%; 10 beats, 1 miss, 0 met estimates
Average EPS surprise: +207.03%; 11 comparable reports
Latest EPS result: 0.01; Estimate -0.19 · Beat by 105.32%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$79.50

7.55% downside

Past 12 months12-month forecastHigh $90.00Average $79.50Low $63.00

Recent analyst actions

10 institutions

JefferiesupgradeHoldBuyMay 9, 2025

TD SecuritiesmaintainBuyMay 1, 2025

WGS news

businesswire.comSep 1, 2026

GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree

GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.

Read source

gurufocus.comAug 26, 2026

GeneDx Holdings Corp (WGS) Shares Surge 3.3% -- What GF Score of 65 Tells Investors

On August 26, 2026, GeneDx Holdings Corp (WGS) shares rose 3.3%, bringing the current price to $90.28. The stock is trading within a 52-week range of $32.21 to

Read source

benzinga.comAug 26, 2026

Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside

Bears have piled into a familiar batch of volatile, heavily bet-against names, and nowhere is the wager bigger than on Venture Global, Inc. (NYSE:VG). More than 80% of its float is sold short, the steepest ratio on the…

Read source

gurufocus.comAug 24, 2026

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's

[url="]GeneDx[/url] (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new data publish

Read source

businesswire.comAug 24, 2026

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children's show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.

Read source

zacks.comAug 19, 2026

Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?

GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Read source